These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35752771)

  • 21. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: A prospective randomized controlled trial.
    Wang Y; Zhao HW; Wang CF; Fan CY; Zhang XJ; Zhu Y; Luo DF; Yu GN; Hou AJ; Luan B
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):825-831. PubMed ID: 30724035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
    Shah A; Feldman DN
    Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial.
    Venetsanos D; Sederholm Lawesson S; Fröbert O; Omerovic E; Henareh L; Robertsson L; Linder R; Götberg M; James S; Alfredsson J; Erlinge D; Swahn E
    Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):502-509. PubMed ID: 30351167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
    Chang CC; Chichareon P; Modolo R; Takahashi K; Kogame N; Tomaniak M; Gao C; Royaards KJ; Cequier A; Oldroyd K; Steg PG; Hamm C; Jüni P; Valgimigli M; Windecker S; Onuma Y; Stables RH; Jan van Geuns R; Serruys PW
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):22-30. PubMed ID: 31841136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention.
    Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction.
    Wang ZD; Chen YX; Liu M; Li P; Liang XW; Zhu XZ; Xie WC; Liao W
    Clin Appl Thromb Hemost; 2022; 28():10760296221077973. PubMed ID: 36520539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meng S; Xu J; Guo L; Huang R
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction.
    Chen H; Yu X; Kong X; Li L; Wu J; Ma L
    J Int Med Res; 2020 Sep; 48(9):300060520947942. PubMed ID: 32985292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: A single-center pilot study.
    Li C; Xu R; Shen Y; Dai Y; Zhang F; Ma J; Ge L; Qian J; Ge J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):679-685. PubMed ID: 28766879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periprocedural Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction.
    Rashid MK; Singh K; Bernick J; Wells GA; Hibbert B; Russo J; So DY; Le May MR;
    J Invasive Cardiol; 2019 Dec; 31(12):E387-E391. PubMed ID: 31786531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
    Zeymer U; van 't Hof A; Adgey J; Nibbe L; Clemmensen P; Cavallini C; ten Berg J; Coste P; Huber K; Deliargyris EN; Day J; Bernstein D; Goldstein P; Hamm C; Steg PG
    Eur Heart J; 2014 Sep; 35(36):2460-7. PubMed ID: 24849104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
    Kaul U; Dua A; Sethi AK; Arambam P; Seth A
    Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
    Sardi GL; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?
    Mavrakanas TA; Chatzizisis YS
    Expert Rev Cardiovasc Ther; 2015; 13(8):893-5. PubMed ID: 26138859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.